# Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026
Canonical URL: https://biopharmsignal.com/news/ESPR/esperion-showcases-new-data-from-clear-outcomes-highlighting-value-of-nexletolr-bempedoic-acid-at-the-american-college-of-cardiology-s-annual-scientific-session-2026
Ticker: ESPR
Company: Esperion Therapeutics
Source: Esperion Therapeutics
Published: 2026-03-30 12:00 EST
Original Source URL: https://www.esperion.com
## Summary

–  Analysis Demonstrated 22% Reduced Risk of Ischemic Stroke for Patients Taking Bempedoic Acid Compared to Placebo – – Analysis of CLEAR Outcomes Reports Bempedoic Acid Reduced MACE in High-Risk Patients with Autoimmune or Inflammatory Diseases (AIID) Similarly to Those Without AIID – ANN ARBOR,

## Article Body
–  Analysis Demonstrated 22% Reduced Risk of Ischemic Stroke for Patients Taking Bempedoic Acid Compared to Placebo – – Analysis of CLEAR Outcomes Reports Bempedoic Acid Reduced MACE in High-Risk Patients with Autoimmune or Inflammatory Diseases (AIID) Similarly to Those Without AIID – ANN ARBOR,
## Recent Company News
- 2026-05-26 12:00 EST — [Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026](https://biopharmsignal.com/news/ESPR/esperion-presents-new-data-from-clear-outcomes-and-the-clear-path-phase-2-pediatric-study-at-the-european-atherosclerosis-society-congress-2026) — Source: Esperion Therapeutics
- 2026-05-14 20:30 EST — [Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ESPR/esperion-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Esperion Therapeutics
- 2026-05-13 12:00 EST — [Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026](https://biopharmsignal.com/news/ESPR/esperion-announces-two-new-analyses-supporting-bempedoic-acid-to-reduce-ldl-c-levels-to-be-presented-at-the-european-atherosclerosis-society-eas-congress-2026) — Source: Esperion Therapeutics
- 2026-05-01 11:00 EST — [Esperion to be Acquired by ARCHIMED](https://biopharmsignal.com/news/ESPR/esperion-to-be-acquired-by-archimed) — Source: Esperion Therapeutics
- 2026-04-23 12:00 EST — [Esperion to Report First Quarter 2026 Financial Results on May 7](https://biopharmsignal.com/news/ESPR/esperion-to-report-first-quarter-2026-financial-results-on-may-7) — Source: Esperion Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)